Skip to content

Determination of the Median Effective Dose of Remifentanil for Conscious Analgesic Gastroscopy with Concurrent Intravenous Lidocaine in High Aspiration-Risk Patients

Determination of the Median Effective Dose of Remifentanil for Conscious Analgesic Gastroscopy with Concurrent Intravenous Lidocaine in High Aspiration-Risk Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122141
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux aspiration

Interventions

Remifentanil:Modified sequential method

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.ASA physical status class II-III; 2.Aged 40-65 years; 3.Scheduled for elective post-gastrectomy gastroscopic surveillance (for gastric cancer).

Exclusion criteria

Exclusion criteria: 1.Allergy to opioids or amide-type local anesthetics; 2.Severe impairment of cardiac, pulmonary, hepatic, or renal function; 3.Chronic use of opioid or benzodiazepine analgesics/sedatives; 4.Anticipated difficult airway (e.g., Mallampati class IV, inter-incisor distance <3 cm); 5.Severe dysfunction of the heart, liver, brain, lungs, kidneys, or coagulation system; 6.Presence of psychiatric or cognitive disorders that preclude cooperation with assessments.

Design outcomes

Primary

MeasureTime frame
Buck;Body movement;

Secondary

MeasureTime frame
Mean Arterial Pressure(MAP);Pulse Oxygen Saturation(SpO?);Heart Rate(HR);

Countries

China

Contacts

Public ContactXiaopeng Wang

Weifang People's Hospital

15621761218@163.com+86 536 784 3657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026